AVIEW LCS vs Tempus ECG-Low EF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, AVIEW LCS, provides a comprehensive cardiopulmonary assessment from CT scans, including coronary artery calcification scoring and lung health analysis. Tool B, Tempus ECG-Low EF, specializes in detecting signs of low left ventricular ejection fraction from ECG recordings to aid in heart failure risk identification. While both contribute to cardiology, they utilize different data modalities (CT vs. ECG) and focus on distinct cardiac conditions and diagnostic points.
Choose AVIEW LCS if…
Choose AVIEW LCS if your facility requires a comprehensive, AI-driven solution for multi-faceted cardiopulmonary assessment from low-dose CT scans. This tool is ideal for lung cancer screening programs that also benefit from concurrent, automated analysis of COPD and coronary artery calcification, streamlining diagnostics and follow-up workflows.
View AVIEW LCS →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your clinical setting needs an efficient, non-invasive AI tool to screen for low left ventricular ejection fraction using standard 12-lead ECGs. This is particularly useful for quickly identifying patients 40 years or older at risk of heart failure in primary care, emergency, or internal medicine, prompting further cardiac evaluation.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | Tempus ECG-Low EF |
|---|---|---|
| Pricing | Subscription or one-off payment | Unknown |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Integrates with current ECG platforms and electronic health records (EHRs). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | Tempus ECG-Low EF |
|---|---|---|
| Primary Purpose | AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. | AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. |
| Company | Coreline Soft Co. | Tempus AI |
| Primary Data Input | Low-dose CT scan | 12-lead ECG recordings |
| Key Functionality | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Emphysema quantification, Coronary Artery Calcification (CAC) scoring. | Detects signs of low Left Ventricular Ejection Fraction (LVEF u226440%), analyzes resting, non-ambulatory 12-lead ECG recordings. |
| Output Type | Nodule volume quantification and 3D segmentation, comprehensive, automated report generation. | Binary output (Low LVEF Detected / Not Detected). |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and Tempus ECG-Low EF.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
AVIEW LCS is an AI-powered solution for comprehensive cardiopulmonary assessment from low-dose CT scans, focusing on lung nodule detection and analysis for lung cancer screening, COPD quantification, and coronary artery calcification scoring. Tempus ECG-Low EF analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure.
AVIEW LCS analyzes low-dose CT images to provide its assessments. Tempus ECG-Low EF analyzes resting, non-ambulatory 12-lead ECG recordings.
AVIEW LCS provides detailed outputs such as automated lung nodule detection and analysis, Lung-RADS classification, nodule volume quantification, emphysema quantification (LAA index), and coronary artery calcification (CAC) scoring, along with comprehensive automated reports. Tempus ECG-Low EF provides a binary output (Low LVEF Detected / Not Detected) to aid clinicians in further evaluation for low LVEF, and is not intended as a stand-alone diagnostic tool.
AVIEW LCS is designed for Cardiology, Oncology, Pulmonology, and Radiology due to its multi-disease screening capabilities from CT scans. Tempus ECG-Low EF primarily supports Cardiology, Emergency Medicine, and Internal Medicine by aiding in the identification of patients at risk of heart failure.
AVIEW LCS includes features for automated comparison of nodules in follow-up CT scans and nodule volume doubling time calculation to track changes. Tempus ECG-Low EF is not intended for patient monitoring or repeated testing of the same patient within a 12-month period, but a positive result may suggest the need for further clinical evaluation.
More Comparisons
More matchups featuring AVIEW LCS or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.